ALT 74 U/L, AST 38 U/L, GGT 89 U/L, AFU 105 U/L, AFP 17.1 ng/ml, AFP-L3 (-), CEA, CA19-9 (-); Liver diseases - related autoantibodies, AMA-M2, LKM-1, SLA/LP, LC-1, (-); MRI, cirrhosis, multiple sclerotic nodules, parapancreatic lymph nodes, fatty liver, and cholecystitis. This evidence concerns the gene CEACAM5 and liver disorder.